InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
0.00%
)
Bitcoin
60,022.97
(
1.33%
)
Post# of 252590
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: randychub post# 247782

Wednesday, 06/28/2023 3:11:12 PM

Wednesday, June 28, 2023 3:11:12 PM

Post# of 252590
Indeed, LLY's Retatrutide has_safety_issues—the 11-14% arrhythmia rate ought to be quite concerning for a drug that will likely be taken chronically (assuming it makes it to market).

As I noted in a prior post, hitting three targets may not be the way to go.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up